The Aurum Biosciences management team have significant experience in their own fields andthey bring to Aurum the breadth of knowledge that is necessary to drive the development of GOLD technology forward, from pre-clinical testing and into the clinic. Their areas of expertise include medical, pre-clinical scientific, clinical scientific and commercial.
Jim McGuire, CEO
Jim McGuire has over 20 years in healthcare, biotech, medtech with expertise in management, commercialisation, product and manufacturing development, project management and IP. Previously Jim has worked in life science start-ups and was recently the CEO of an NHS spin-out developing surgical devices, taking their innovations into the global market place. He worked in commercialisation and business development at Scottish Health Innovations Ltd, starting as a Business Development Executive Jim was promoted in January 2007 to a position that covered all aspects of the company’s remit. Scottish Health Innovations Ltd develops medical and healthcare technologies arising mainly from the NHS in Scotland, managing the process from evaluation and feasibility through product development to regulatory approval and market.
Gerry McGettigan, Executive Chairman
Gerry, a molecular biologist, has 25 years’ experience in the biotechnology and pharmaceutical industries, in regulatory affairs, clinical development and business roles, and as Non-Executive Director in several Biotech firms. He has worked with large and medium pharma companies (Almirall, Spain and Glaxo, UK) and at The Liposome Company, a US biotechnology firm. In 1998, he founded the European regulatory affairs and product development consultancy, GMG BioBusiness Ltd, which was sold to a top 5 CRO in 2005. In 2006 he became the first CEO of the biotechnology development agency, Biocat, in Barcelona, Spain. Thereafter he set up Kinesys Consulting Ltd, which supports the biopharma industry with Development, Regulatory and Commercial services. In 2104 he assumed the part-time role of COO at amp biosimilars, AG, Germany. In addition to his ongoing activities at Aurum, amp biosimilars and Kinesys, Gerry is Non-Executive Chairman of Clear Surgical.
Dr Graeme Deuchar, R&D Director
Graeme Deuchar has over 15 years experience working as a biomedical research professional. He has an impressive track record of developing and utilising preclinical disease models combined with imaging, in projects designed to improve understanding of disease mechanism and investigate novel diagnostic and therapeutic advances in areas of cardiovascular, pulmonary and neurological medicine. Graeme is a co-founder of Aurum Biosciences Ltd where he advises on planning the current and future research and development programme required to support continued progression of the company’s key technology. Graeme also provides regulatory affairs expertise and has experience in areas related to the regulatory requirements for the development of small molecule and biopharmaceutical medicinal products.
Dr Celestine Santosh, CMO/CSO
Celestine Santosh is a Clinical Consultant Neuroradiologist working in Glasgow, which is one of the largest Neurosciences Unit within the UK. Having started in Clinical Radiology 33 years ago, he then specialised in Neuroradiology over the last 27 years. He has worked in many large specialised hospitals in India and the UK and has been in Glasgow since 2000. He conceived the Glasgow Oxygen Dependent (GOLD) techniques working as a clinician, with a special interest in stroke. This allowed him to understand the need to accurately assess the Penumbra with imaging and also the need for additional treatments for stroke. He was successful with the team, in getting grants and funding for the pre-clinical work. Dr Santosh is a co-founder of Aurum Biosciences Ltd, a practicing clinician and inventor, so in an ideal position to take the GOLD techniques into clinical practice.
Dr David Brennan, Director of Project Management
David Brennan has worked as a clinical scientist for 20 years specialising in Clinical Physics. During that time he has had experience in clinical research and service development. His focus has been in the field of MRI, image analysis and their clinical applications. He is a founding researcher of Aurum Biosciences having provided significant input into the development of the imaging and image analysis. During the course of Aurum’s development David has taken a keen interest in the commercial aspects of the project. He was fortunate enough to have been a student on Cambridge University’s Ignite entrepreneurial course, and MIT’s Entrepreneurship Development Program.